InvestorsHub Logo

DoubleJ23

10/10/13 11:40 AM

#43434 RE: oddone33320 #43433

I just want to piggy back on your comment and ask the board:

Can/should Cellceutix just partner B for ABSSSI applications only? That way we can take a "bad" deal to get some quick cash without dilution and still save all the other B applications for better deals/partnerships?

petemantx

10/10/13 1:15 PM

#43438 RE: oddone33320 #43433

Look at the PR today. The conference (scheduled for early Nov) is primarily aimed at partnerships for new drugs so having Brilacidin named one of the 10 Most Exciting Drugs at the conference is a big deal.

dmattingly62

10/10/13 1:53 PM

#43439 RE: oddone33320 #43433

Leo didn't budget for B and is doing a big dog and pony show next month, only two months after the deal. I'ld say it's pretty clear he's looking for a partner ahead of the trial. We could have one before year end. I say that not out of hopefulness but because of the change from baseline, something I mentioned in another post. This is something i pay attention too. Up to the deal their was a certain pace. There was a pr pace and a general pace at which things were getting done. There had been many delays. That changed. Leo's energy changed. Things are happening very fast now. Look at the things that have changed in the past five weeks: a major acquisition, change in corporate strategy, acceleration of Prurisol development, general energy, acceleration of PR's, I've noticed a deceleration of response to emails ( a good thing ), rapid movement on Brilacidin and for two indications, more updates on K, hiring, folding Kard in, taking over the Kard space at over 15k per month vs $900 for the old space for a 5 year lease vs month to month, priority to up list etc. There are lots of other clues but I just wanted to highlight some of the obvious ones from the past five weeks. I would say we are in the sweet spot. Everything is accelerating. The price will follow. Who knows when but when it does it will be sudden and rapid.